Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
India plays a critical role in Bristol Myers Squibb’s global strategy
The initiative aims to connect startups and tech companies with its business units,
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Subscribe To Our Newsletter & Stay Updated
